Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Lung Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Genistein × Clear all
NCT02567799 2024-01-25

NSCLC

Humanetics Corporation

Phase 1/2 Completed
21 enrolled 32 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01628471 2015-09-23

MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Uman Pharma

Phase 1/2 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01182246 2014-04-23

AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

Axcentua Pharmaceuticals AB

Phase 1/2 Unknown
44 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡